Tardive dyskinesia: Eliminated, forgotten, or overshadowed?

Current Opinion in Psychiatry

Volumn 20, Issue 2, 2007, Pages 131-137

  Remington, Gary ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotics; Side effects; Tardive dyskinesia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ABSENCE OF SIDE EFFECTS; DIABETES MELLITUS; DOSE RESPONSE; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG USE; EXTRAPYRAMIDAL SYNDROME; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICAL LIABILITY; NONHUMAN; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; DRUG TOXICITY; DYSKINESIA, DRUG-INDUCED; EVIDENCE-BASED MEDICINE; HUMANS; NEUROLOGIC EXAMINATION; PRODUCT SURVEILLANCE, POSTMARKETING; RISK;

EID: 33846837063     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328017f6b1     Document Type: Review

References (79)

1. Crane GE. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am J Psychiatry 1968; 124 (suppl):40-48.
2. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324:746-754.
3. Fleischhacker WW, Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 1997; 53:915-929.
4. Emsley R, Oosthuizen P. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 2004; 7:219-238.
5. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003; 29:531-540.
6. Edlinger M, Hausmann A, Kemmler G, Kurz M, et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res 2005; 77:25-34.
7. Newcomer J. Second-generation antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19:1-93.
8. Poulin MJ, Cortese L, Williams R, et al. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. Can J Psychiatry 2005; 50:555-562.
9. Melkersson KI, Dahl ML, Hulting AL. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl) 2004; 175:1-6.
10. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349.
11. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005; 66:183-194.
12. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601.
13. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996; 124:188-196.
14. Lieberman J, Johns C, Cooper T, et al. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology (Berl) 1989; 99 (suppl):S54-S59.
15. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993; 54:327-330.
16. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414-425.
17. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21:589-598. A broad overview of the evidence on risk of tardive dyskinesia with atypical versus typical antipsychotics is provided, highlighting limitations to the existing data.
18. Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001; 62:273-281.
19. Rein W, L'Heritier C. Treatment-emergent tardive dyskinesia in the long-term treatment of schizophrenia: a comparison of amisulpride and haloperidol [abstract]. J Eur Coll Neuropsychopharmacol 1999; 9:282.
20. Glazer WM, Morgenstern H, Pultz JA, et al. Incidence of tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 13-18 December 1999; Acapulco. Nashville: ACNP; 1999.
21. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346:16-22.
22. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174:23-30.
23. Speller JC, Barnes TR, Curson DA, et al. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms: amisulpride v. haloperidol. Br J Psychiatry 1997; 171:564-568.
24. Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005; 66:1130-1133. Six-month data on over 8500 patients treated with typical or atypical antipsychotics in a naturalistic study design supports the diminished tardive dyskinesia risk of atypicals.
25. Malla AK, Norman RM, Scholten DJ, et al. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry 2001; 62:179-184.
26. Oosthuizen PP, Emsley RA, Maritz JS, et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64:1075-1080.
27. Gharabawi GM, Bossie CA, Zhu Y. New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol. Am J Psychiatry 2006; 163:938-939. Adds to a limited number of reports addressing risk of tardive dyskinesia for atypical versus typical antipsychotics in first episode patients.
28. Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two year data. Schizophr Res 2006; 86:234-243. Adds to a limited number of studies reporting the risk of tardive dyskinesia for an atypical versus typical antipsychotic in first episode patients.
29. Woerner MG, Robinson DG, Alvir JM, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003; 160:1514-1516.
30. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28:995-1003.
31. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61:15-20.
32. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321:1371-1376.
33. Oosthuizen P, Emsley R, Maritz J, et al. Treatment with low-dose haloperidol does not protect against tardive dyskinesia. Schizophr Res 2003; 60 (suppl):364.
34. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157:1150-1155.
35. Jeste DV, Lacro JP, Palmer B, et al. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999; 156:309-311.
36. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47:716-719.
37. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003; 53:1142-1145.
38. Kane JM, Woerner M, Weinhold P, et al. A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 1982; 2:345-349.
39. Kane JM. Tardive dyskinesia circa 2006. Am J Psychiatry 2006; 163:1316-1318.
40. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61:16-21.
41. Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35:187-191.
42. Simpson GM, Varga E. Clozapine: a new antipsychotic agent. Curr Ther Res Clin Exp 1974; 16:679-686.
43. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158:503-510.
44. Pi EH, Simpson GM. Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia. Mod Probl Pharmacopsychiatry 1983; 21:80-86.
45. Littrell KH, Johnson CG, Littrell S, Peabody CD. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry 1998; 55:279-280.
46. Grant MJ, Baldessarini RJ. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 2005; 39:1953.
47. Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004; 65:696-701.
48. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15:36S-44S.
49. Seeman P. Atypical antipsychotics: mechanisms of action. Can J Psychiatry 2002; 47:27-38.
50. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1081-1090.
51. 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000; 152:174-180.
52. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000; 61:5-9.
53. Remington G. Understanding antipsychotic 'atypicality': a clinical and pharmacological moving target. J Psychiatry Neurosci 2003; 28:275-284.
54. Kapur S, Sridhar N, Remington G. The newer antipsychotics: underlying mechanisms and the new clinical realities. Curr Opin Psychiatry 2004; 15:115-121.
55. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50:873-883.
56. Lang DJ, Kopala LC, Vandorpe RA, et al. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry 2004; 161:1829-1836.
57. Corson PW, Nopoulos P, Miller DD, et al. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 1999; 156:1200-1204.
58. Andersson C, Hamer RM, Lawler CP, et al. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology 2002; 27:143-151.
59. Ahmed S, Chengappa KN, Naidu VR, et al. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 1998; 59:472-477.
60. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63:12-19.
61. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16:23-45.
62. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005; 28:191-208. Highlights differences in side effects between atypical antipsychotics, which may, as with the typical agents, become the most important issue in antipsychotic choice.
63. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002; 28:75-84.
64. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003; 64:984-989.
65. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10 000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006; 163:1438-1440. Further evidence from a large sample linking EPS as a risk factor in tardive dyskinesia - presence of other EPS doubles likelihood of developing tardive dyskinesia.
66. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8:21S-26S.
67. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514-520.
68. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544.
69. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286-293.
70. 2 atypical antipsychotics. Am J Psychiatry 2005; 162:1984-1985.
71. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998; 3:123-134.
72. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005; 20:183-198.
73. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60:974-977.
74. 2 receptor occupancy? Neurosci Biobehav Rev 2002; 26:361-380.
75. 2 occupancy) may influence risk of TD.
76. 2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006; 163:396-401.
77. Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004; 18:113-132.
78. Kasper S, Lowry AJ, Hodge A, et al. Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res 2006; 81:139-143.
79. de Leon J. Tardive dyskinesia in the naturalistic setting: the efficacy of atypical and typical antipyschotics. Biol Psychiatry 2006; 59:1345.